Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
uniQure N.V.
QURE
$26.46
Name : uniQure N.V.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,668,765,568.00
EPSttm : -3.42
finviz dynamic chart for QURE
uniQure N.V.
$26.46
2.00%
$0.54
QURE — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

18.2

Margin Of Safety %

Put/Call OI Ratio

0.18

EPS Next Q Diff

0.1

EPS Last/This Y

0.47

EPS This/Next Y

0.56

Price

26.5

Target Price

38.33

Analyst Recom

1.57

Performance Q

44.91

Upside

-391.8%

Beta

1.02

Ticker: QURE




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-05-11QURE27.660.180.12137811
2026-05-12QURE29.110.180.13139039
2026-05-13QURE29.150.190.10144217
2026-05-14QURE27.80.190.18147064
2026-05-15QURE27.050.190.37148918
2026-05-18QURE24.910.170.14110484
2026-05-19QURE24.710.160.24115969
2026-05-20QURE24.590.160.37117072
2026-05-21QURE24.80.170.74117414
2026-05-22QURE24.150.170.37117986
2026-05-26QURE25.180.170.18118644
2026-05-27QURE25.140.170.70119547
2026-05-28QURE24.820.170.98120177
2026-05-29QURE28.490.170.11120640
2026-06-02QURE26.780.180.06127088
2026-06-03QURE29.860.180.13125981
2026-06-04QURE27.980.170.19134797
2026-06-05QURE26.460.180.11141242
2026-06-08QURE27.030.180.11143225
2026-06-09QURE26.490.180.26144092
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-05-11QURE27.66-19.7- -3.02
2026-05-12QURE29.12-19.0- -3.01
2026-05-13QURE29.15-20.7- -3.01
2026-05-14QURE27.76-20.7- -2.98
2026-05-15QURE27.03-19.9- -2.99
2026-05-18QURE24.90-19.9- -2.99
2026-05-19QURE24.69-19.9- -2.99
2026-05-20QURE24.58-19.9- -2.99
2026-05-21QURE24.78-19.9- -2.99
2026-05-22QURE24.19-19.9- -2.99
2026-05-26QURE25.15-19.9- -2.99
2026-05-27QURE25.15-19.9- -2.99
2026-05-28QURE24.85-19.9- -2.99
2026-05-29QURE28.55-19.9- -2.99
2026-06-01QURE28.22-19.9- -2.99
2026-06-02QURE26.78-19.9- -2.99
2026-06-03QURE29.91-19.9- -2.99
2026-06-04QURE27.99-19.9- -2.99
2026-06-05QURE26.54-19.9- -2.99
2026-06-08QURE27.02-19.9- -2.99
2026-06-09QURE26.50-19.9- -2.99
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-05-11QURE-3.360.3719.26
2026-05-12QURE-3.310.3718.72
2026-05-13QURE-4.340.3718.44
2026-05-14QURE-4.340.3718.44
2026-05-15QURE-4.340.3718.44
2026-05-18QURE-4.34-4.5818.76
2026-05-19QURE-3.52-4.5818.76
2026-05-20QURE-3.52-4.5818.76
2026-05-21QURE-3.52-4.5818.76
2026-05-22QURE-3.52-4.5819.26
2026-05-26QURE-2.73-5.6719.26
2026-05-27QURE-2.73-5.6719.26
2026-05-28QURE-2.73-5.6718.39
2026-05-29QURE-2.73-5.6718.20
2026-06-02QURE-2.99-6.2318.20
2026-06-03QURE-2.99-6.2318.20
2026-06-04QURE-2.99-6.2318.20
2026-06-05QURE-2.99-6.2318.20
2026-06-08QURE-3.03-6.2918.20
2026-06-09QURE-3.03-6.2918.20
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.85

Avg. EPS Est. Current Quarter

-0.72

Avg. EPS Est. Next Quarter

-0.75

Insider Transactions

-3.03

Institutional Transactions

-6.29

Beta

1.02

Average Sales Estimate Current Quarter

4

Average Sales Estimate Next Quarter

Fair Value

Quality Score

41

Growth Score

27

Sentiment Score

8

Actual DrawDown %

62.9

Max Drawdown 5-Year %

-90.1

Target Price

38.33

P/E

Forward P/E

PEG

P/S

91.46

P/B

11.17

P/Free Cash Flow

EPS

-3.51

Average EPS Est. Cur. Y​

-2.99

EPS Next Y. (Est.)

-2.44

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1154.42

Relative Volume

0.56

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

QURE Healthcare
$26.46
📉
Swing / Pullback
Buy the dip on strong trends
50 /100
WEAK
Trend
8/20
Pullback
11/25
Volume
11/15
Valuation
12/20
TP/AR
1/10
Options
7/10
RSI
54.3
Range 1M
37.6%
🚀
Momentum Growth
Ride accelerating trends
N/A
28 /100
WEAK
Momentum
3/25
Growth
10/30
Estimates
1/20
Inst/Vol
4/15
Options
10/10
EPS Yr
-1.4%
EPS NY
13.2%
52W%
28.5%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +44.9% upside
Quality
3/30
Valuation
11/30
Growth
7/25
Stability
5/10
LT Trend
4/5
Upside
+44.9%
Quality
41
uniQure N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 221
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE

Latest News

Caricamento notizie per QURE
stock quote shares QURE – uniQure N.V. Stock Price stock today
news today QURE – uniQure N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch QURE – uniQure N.V. yahoo finance google finance
stock history QURE – uniQure N.V. invest stock market
stock prices QURE premarket after hours
ticker QURE fair value insiders trading